Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Sulforaphane increases the efficacy of doxorubicin in mouse fibroblasts characterized by p53 mutations.

Mutation research - 10 Oct 2006

Fimognari Carmela, Nüsse Michael, Lenzi Monia, Sciuscio Davide, Cantelli-Forti Giorgio, Hrelia Patrizia

Abstract excerpt

One novel strategy for increasing cancer chemotherapy efficacy and reversing chemoresistance involves co-administration of natural chemopreventive compounds alongside standard chemotherapeutic protocols. Sulforaphane is a particularly promising chemopreventive agent, which has been shown to exert proapoptotic effects on tumor cells containing p53 mutations. The p53(Ser220) mutation has been implicated in reduced...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Antibiotics, Antineoplastic
Share to Anticarcinogenic Agents

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Caspases

Share to Cell Membrane Permeability

Share to Doxorubicin

Share to Drug Synergism

Share to Enzyme Activation

Share to Isothiocyanates

Source

Identifiers

PMID: 16843502
DOI: 10.1016/j.mrfmmm.2006.06.001

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 10 closest

Sulforaphane increases the efficacy of doxorubicin in mouse fibroblasts characterized by p53 mutations.PMID 16843502Read ↗

Combination of doxorubicin and sulforaphane for reversing doxorubicin-resistant phenotype in mouse fibroblasts with p53Ser220 mutation.Semantic proximity Read ↗

A mutated p53 status did not prevent the induction of apoptosis by sulforaphane, a promising anti-cancer drug.Semantic proximity Read ↗

p53 prevents doxorubicin cardiotoxicity independently of its prototypical tumor suppressor activitiesSemantic proximity Read ↗

Inhibition of cell cycle and induction of apoptosis by sulforaphane in cell lines carrying various inherited BRCA1 mutations.Semantic proximity Read ↗

An evaluation of small-molecule p53 activators as chemoprotectants ameliorating adverse effects of anticancer drugs in normal cellsSemantic proximity Read ↗

Synergistic effects of the purine analog sulfinosine and curcumin on the multidrug resistant human non-small cell lung carcinoma cell line (NCI-H460/R).Semantic proximity Read ↗

Jasmonates induce nonapoptotic death in high-resistance mutant p53-expressing B-lymphoma cells.Semantic proximity Read ↗

A ruthenium(II)-curcumin compound modulates NRF2 expression balancing the cancer cell death/survival outcome according to p53 status.Semantic proximity Read ↗

Mutant p53 exhibits trivial effects on mitochondrial functions which can be reactivated by ellipticine in lymphoma cells.Semantic proximity Read ↗

A thiol-bound drug reservoir enhances APR-246-induced mutant p53 tumor cell death.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.